| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4268417 | British Journal of Medical and Surgical Urology | 2011 | 7 Pages |
Abstract
SummaryThe publication of phase III data on cabazitaxel in the management of metastatic castrate-resistant prostate cancer in men previously treated with docetaxel demonstrated, for the first time, that a survival benefit can be achieved in this patient group. Optimal use of cabazitaxel will depend on appropriate patient selection and on effective management of the side effects, which have been shown to be predictable and preventable/treatable using interventions that are already familiar to chemotherapy clinics.
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
Anna Lydon,